Step by Step


11/7/2017 - Medical Grand Rounds: Developing an antidote for CO poisoning: From Bench to Bedside to Commercialization





Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the management options for carbon monoxide poisoning.
  • Recognize the mechanisms of carbon monoxide poisoning.
  • Learn about the FDA regulatory therapeutic approval process.

Suggested Additional Reading:

  1. Weaver et al 2007
  2. Azorov et al, Sci Transl. Med. 8, 368ra 173 (2016)
  3. Moss et al. Circulation. 2003;108:II-90-II-97.
  4. DiMasi et al. Journal of Health Economics 2016;47:20-33.

Jason Rose, M.D., M.B.A. — Assistant Professor Of Medicine Division of Pulmonary, Allergy and Critical Care Medicine Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute
Dr Rose is a stockholder with Globin Solutions, Inc. Dr. Rose is also CEO & President of the Board of Directors; Globin Solutions, Inc.
Mark T. Gladwin, M.D — Jack D. Myers Professor and Chair Chairman of the Department of Medicine Director, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute UPMC and the University of Pittsburgh School of Medicine
Dr. Gladwin has a sponsored research agreement with Bayer, collaboration with United Therapeutics. He is also the Chairman of the Board of Directors, Globin Solutions, Inc.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.